408 related articles for article (PubMed ID: 27657681)
21. The pharmacological chaperone 1-deoxygalactonojirimycin increases alpha-galactosidase A levels in Fabry patient cell lines.
Benjamin ER; Flanagan JJ; Schilling A; Chang HH; Agarwal L; Katz E; Wu X; Pine C; Wustman B; Desnick RJ; Lockhart DJ; Valenzano KJ
J Inherit Metab Dis; 2009 Jun; 32(3):424-40. PubMed ID: 19387866
[TBL] [Abstract][Full Text] [Related]
22. Mutation spectrum of α-Galactosidase gene in Japanese patients with Fabry disease.
Kobayashi M; Ohashi T; Kaneshiro E; Higuchi T; Ida H
J Hum Genet; 2019 Jul; 64(7):695-699. PubMed ID: 30988410
[TBL] [Abstract][Full Text] [Related]
23. Chaperone Therapy in Fabry Disease.
Weidemann F; Jovanovic A; Herrmann K; Vardarli I
Int J Mol Sci; 2022 Feb; 23(3):. PubMed ID: 35163813
[TBL] [Abstract][Full Text] [Related]
24. [Chaperone molecules: The example of Fabry disease].
Barbey F; Monney P; Dormond O
Nephrol Ther; 2021 Apr; 17S():S11-S22. PubMed ID: 33910691
[TBL] [Abstract][Full Text] [Related]
25. Challenges in Fabry disease: the combination of two individually amenable
Fernandes RM; Bento D; Marques N; Azevedo O; Mota T; Costa H; Santo ME; Silva DC; Jesus I
Future Cardiol; 2023 Jan; 19(1):39-43. PubMed ID: 36695159
[TBL] [Abstract][Full Text] [Related]
26. Misfolding of Lysosomal α-Galactosidase a in a Fly Model and Its Alleviation by the Pharmacological Chaperone Migalastat.
Braunstein H; Papazian M; Maor G; Lukas J; Rolfs A; Horowitz M
Int J Mol Sci; 2020 Oct; 21(19):. PubMed ID: 33036426
[TBL] [Abstract][Full Text] [Related]
27. Treatment of Fabry's Disease With Migalastat: Outcome From a Prospective Observational Multicenter Study (FAMOUS).
Lenders M; Nordbeck P; Kurschat C; Karabul N; Kaufeld J; Hennermann JB; Patten M; Cybulla M; Müntze J; Üçeyler N; Liu D; Das AM; Sommer C; Pogoda C; Reiermann S; Duning T; Gaedeke J; Stumpfe K; Blaschke D; Brand SM; Mann WA; Kampmann C; Muschol N; Canaan-Kühl S; Brand E
Clin Pharmacol Ther; 2020 Aug; 108(2):326-337. PubMed ID: 32198894
[TBL] [Abstract][Full Text] [Related]
28. Treatment of Fabry Disease management with migalastat-outcome from a prospective 24 months observational multicenter study (FAMOUS).
Lenders M; Nordbeck P; Kurschat C; Eveslage M; Karabul N; Kaufeld J; Hennermann JB; Patten M; Cybulla M; Müntze J; Üçeyler N; Liu D; Das AM; Sommer C; Pogoda C; Reiermann S; Duning T; Gaedeke J; von Cossel K; Blaschke D; Brand SM; Mann WA; Kampmann C; Muschol N; Canaan-Kühl S; Brand E
Eur Heart J Cardiovasc Pharmacother; 2022 May; 8(3):272-281. PubMed ID: 35512362
[TBL] [Abstract][Full Text] [Related]
29. Assessment of plasma lyso-Gb
Bichet DG; Aerts JM; Auray-Blais C; Maruyama H; Mehta AB; Skuban N; Krusinska E; Schiffmann R
Genet Med; 2021 Jan; 23(1):192-201. PubMed ID: 32994552
[TBL] [Abstract][Full Text] [Related]
30. Migalastat: First Global Approval.
Markham A
Drugs; 2016 Jul; 76(11):1147-52. PubMed ID: 27351440
[TBL] [Abstract][Full Text] [Related]
31. Baseline Characteristics of Fabry Disease "Amenable" Migalastat Patients in Argentinian Cohort.
Jaurretche S; Alonso S; Calvo M; Fernandez S; Figueredo H; Galli B; Marin I; Martinez A; Mattausch S; Perretta F; Politei J; Rolon JI; Calabrese E
Glob Health Epidemiol Genom; 2024; 2024():9293896. PubMed ID: 38410281
[TBL] [Abstract][Full Text] [Related]
32. Migalastat improves diarrhea in patients with Fabry disease: clinical-biomarker correlations from the phase 3 FACETS trial.
Schiffmann R; Bichet DG; Jovanovic A; Hughes DA; Giugliani R; Feldt-Rasmussen U; Shankar SP; Barisoni L; Colvin RB; Jennette JC; Holdbrook F; Mulberg A; Castelli JP; Skuban N; Barth JA; Nicholls K
Orphanet J Rare Dis; 2018 Apr; 13(1):68. PubMed ID: 29703262
[TBL] [Abstract][Full Text] [Related]
33. Oral Chaperone Therapy Migalastat for Treating Fabry Disease: Enzymatic Response and Serum Biomarker Changes After 1 Year.
Müntze J; Gensler D; Maniuc O; Liu D; Cairns T; Oder D; Hu K; Lorenz K; Frantz S; Wanner C; Nordbeck P
Clin Pharmacol Ther; 2019 May; 105(5):1224-1233. PubMed ID: 30506669
[TBL] [Abstract][Full Text] [Related]
34. Pharmacological chaperone therapy for Fabry disease.
Ishii S
Proc Jpn Acad Ser B Phys Biol Sci; 2012; 88(1):18-30. PubMed ID: 22241068
[TBL] [Abstract][Full Text] [Related]
35. Safety and pharmacodynamic effects of a pharmacological chaperone on α-galactosidase A activity and globotriaosylceramide clearance in Fabry disease: report from two phase 2 clinical studies.
Germain DP; Giugliani R; Hughes DA; Mehta A; Nicholls K; Barisoni L; Jennette CJ; Bragat A; Castelli J; Sitaraman S; Lockhart DJ; Boudes PF
Orphanet J Rare Dis; 2012 Nov; 7():91. PubMed ID: 23176611
[TBL] [Abstract][Full Text] [Related]
36. Long-term multisystemic efficacy of migalastat on Fabry-associated clinical events, including renal, cardiac and cerebrovascular outcomes.
Hughes DA; Bichet DG; Giugliani R; Hopkin RJ; Krusinska E; Nicholls K; Olivotto I; Feldt-Rasmussen U; Sakai N; Skuban N; Sunder-Plassmann G; Torra R; Wilcox WR
J Med Genet; 2023 Jul; 60(7):722-731. PubMed ID: 36543533
[TBL] [Abstract][Full Text] [Related]
37. Therapy of Fabry disease with pharmacological chaperones: from in silico predictions to in vitro tests.
Andreotti G; Citro V; De Crescenzo A; Orlando P; Cammisa M; Correra A; Cubellis MV
Orphanet J Rare Dis; 2011 Oct; 6():66. PubMed ID: 22004918
[TBL] [Abstract][Full Text] [Related]
38. Switch from enzyme replacement therapy to oral chaperone migalastat for treating fabry disease: real-life data.
Riccio E; Zanfardino M; Ferreri L; Santoro C; Cocozza S; Capuano I; Imbriaco M; Feriozzi S; Pisani A;
Eur J Hum Genet; 2020 Dec; 28(12):1662-1668. PubMed ID: 32647377
[TBL] [Abstract][Full Text] [Related]
39. A Systematic Review on Safety and Efficacy of Migalastat for the treatment of Fabry's Disease.
Majid H; Verma N; Bhandari S; Gupta S; Nidhi
Expert Opin Pharmacother; 2024 Apr; 25(6):769-782. PubMed ID: 38753367
[TBL] [Abstract][Full Text] [Related]
40. Long-term follow-up of renal function in patients treated with migalastat for Fabry disease.
Bichet DG; Torra R; Wallace E; Hughes D; Giugliani R; Skuban N; Krusinska E; Feldt-Rasmussen U; Schiffmann R; Nicholls K
Mol Genet Metab Rep; 2021 Sep; 28():100786. PubMed ID: 34401344
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
